Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERACT4: Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke
NCT03790800Phase 3Completed
- Sponsor
- The George Institute for Global Health
- Start
- Mar 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of urapidil in acute stroke (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: Level of physical function (mRS) at 90 days. Started Mar 2020; status: completed.
02
Drugs
urapidil
03
Conditions
acute stroke
Beyond the preview
Go deeper on NCT03790800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790800.